Factor Xa inhibitors: critical considerations for clinical development and testing.

Richard C Becker

Journal of thrombosis and thrombolysis 2021 Aug

filter terms:

The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor bearing cells and the interface of coagulation proteins, platelets, mononuclear cells and the nuclear constituents of inflammatory cells. The goal for developing direct oral FXa inhibitors was to achieve rapid, selective, predictable, safe and effective anticoagulation across a broad group of patients expected to derive benefit. The history and development in patient care are exemplars of knowledge, translation and collaboration between the public and private sectors. © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Citation

Richard C Becker. Factor Xa inhibitors: critical considerations for clinical development and testing. Journal of thrombosis and thrombolysis. 2021 Aug;52(2):397-402